iSpecimen Inc.
ISPCNasdaq
$2.10
↓ -5.0%Jul 17 close · end-of-day
Price
1Y↓ -95.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$716,891.70
Enterprise Value
-$2.1M
P/E
0.1
P/S
0.7
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.0M
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-961.4%
Net Margin
-1080.7%
ROE
-1364.1%
ROIC
—
Debt / Equity
—
Net Cash
$2.8M
Return 1Y
-94.9%
Company profile
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with healthcare provider organizations. Cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
- CEO
- Tracy Curley
- Sector
- Services
- Industry
- Business Services
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- ispecimen.com
Earnings
ISPC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$156,009.00↓ -85.2%
Diluted EPS-$6.66↓ -76.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $11.1M | $10.4M | $9.9M | $9.3M | $1.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.4M | -$5.9M | -$10.2M | -$11.2M | -$12.7M | -$9.0M |
| Net income | -$4.7M | -$9.0M | -$10.2M | -$11.1M | -$12.5M | -$10.5M |
| Diluted EPS | -$4.97 | -$2.09 | -$1.16 | -$24.55 | -$17.58 | -$2.28 |
| Operating cash flow | -$288,380.00 | -$10.7M | -$5.8M | -$5.8M | -$8.3M | -$4.2M |
| Free cash flow | -$288,806.00 | -$10.7M | -$6.0M | -$5.8M | -$8.3M | -$4.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -29.4% | -53.2% | -97.9% | -112.5% | -137.0% | -465.4% |
| Net margin | -56.8% | -80.5% | -98.5% | -111.8% | -134.5% | -543.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9M | $2.7M | $1.5M | $1.1M | $713,135.00 | $106,592.00 | $51,761.00 | $156,009.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.2M | -$1.7M | -$5.8M | -$1.6M | -$1.8M | -$2.8M | -$2.7M | -$2.5M |
| Net income | -$2.1M | -$1.4M | -$6.0M | -$1.7M | -$1.0M | -$2.8M | -$5.0M | -$2.3M |
| Diluted EPS | -$3.72 | -$2.10 | -$5.40 | -$28.55 | -$0.42 | -$0.48 | $27.17 | -$6.66 |
| Operating cash flow | -$1.5M | -$1.1M | -$3.6M | -$1.1M | -$192,234.00 | -$2.0M | -$916,923.00 | -$3.4M |
| Free cash flow | -$1.5M | -$1.1M | -$3.6M | — | — | -$2.0M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -76.2% | -64.1% | -395.8% | -154.9% | -255.4% | -2655.2% | -5192.9% | -1627.1% |
| Net margin | -73.6% | -54.1% | -409.8% | -156.8% | -146.9% | -2608.7% | -9662.2% | -1458.4% |
Company news
Apr 9, 2026
Mar 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.